ABBV Jan 2023 115.000 call
| Previous close | 40.80 |
| Open | 40.80 |
| Bid | 42.85 |
| Ask | 43.25 |
| Strike | 115.00 |
| Expiry date | 2023-01-20 |
| Day's range | 40.80 - 40.80 |
| Contract range | N/A |
| Volume | |
| Open interest | 2.7k |
- Motley Fool
3 Dividend Stocks That Should Pay You for the Rest of Your Life
Now could be a great time to put that cash to use toward an investment in these three Dividend Kings that could provide robust returns for a lifetime. Shares of AbbVie (NYSE: ABBV), Lowe's (NYSE: LOW), and Parker Hannifin (NYSE: PH) more than tripled over the past 10 years as investor confidence remained strong. AbbVie was spun off from Abbott Labs in 2013 as a research-based pharmaceutical business.
- PR Newswire
AbbVie to Showcase Depth of Gastroenterology Portfolio and Pipeline at Digestive Disease Week®
AbbVie (NYSE: ABBV) today announced that 27 abstracts across its gastroenterology portfolio will be presented at the Digestive Disease Week (DDW) Annual Meeting, May 21-24, 2022, in San Diego and virtually.
- PR Newswire
AbbVie and Cugene Announce Collaboration in Autoimmune Diseases
AbbVie (NYSE: ABBV) and Cugene Inc., a clinical-stage biotechnology company focused on developing next-generation precision immunology and oncology medicines to treat autoimmune disease and cancer, today announced an exclusive worldwide license option agreement for CUG252, a potential best-in-class Treg-selective IL-2 mutein, as well as other novel IL-2 muteins, for the potential treatment of autoimmune and inflammatory diseases.
